KR20220156813A - 로다트리스타트로 폐동맥 고혈압을 치료하기 위한 투여형태 및 방법 - Google Patents

로다트리스타트로 폐동맥 고혈압을 치료하기 위한 투여형태 및 방법 Download PDF

Info

Publication number
KR20220156813A
KR20220156813A KR1020227030098A KR20227030098A KR20220156813A KR 20220156813 A KR20220156813 A KR 20220156813A KR 1020227030098 A KR1020227030098 A KR 1020227030098A KR 20227030098 A KR20227030098 A KR 20227030098A KR 20220156813 A KR20220156813 A KR 20220156813A
Authority
KR
South Korea
Prior art keywords
ethyl
rodatristat
compound
rhodatristat
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227030098A
Other languages
English (en)
Korean (ko)
Inventor
스테판 에이. 링
미셸 팔라시오스
케이틀린 레이가드 크리저
빌 시몬즈
다니엘 패턴슨
Original Assignee
알타반트 사이언시스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알타반트 사이언시스 게엠베하 filed Critical 알타반트 사이언시스 게엠베하
Publication of KR20220156813A publication Critical patent/KR20220156813A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227030098A 2020-01-31 2021-01-29 로다트리스타트로 폐동맥 고혈압을 치료하기 위한 투여형태 및 방법 Withdrawn KR20220156813A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062968651P 2020-01-31 2020-01-31
US62/968,651 2020-01-31
PCT/IB2021/000046 WO2021152398A1 (en) 2020-01-31 2021-01-29 Dosages and methods for treating pulmonary arterial hypertension with rodatristat

Publications (1)

Publication Number Publication Date
KR20220156813A true KR20220156813A (ko) 2022-11-28

Family

ID=75143674

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227030098A Withdrawn KR20220156813A (ko) 2020-01-31 2021-01-29 로다트리스타트로 폐동맥 고혈압을 치료하기 위한 투여형태 및 방법

Country Status (9)

Country Link
US (1) US20230074252A1 (https=)
EP (1) EP4096633A1 (https=)
JP (1) JP2023512025A (https=)
KR (1) KR20220156813A (https=)
CN (1) CN115379825A (https=)
AU (1) AU2021212355A1 (https=)
CA (1) CA3165432A1 (https=)
MX (1) MX2022009254A (https=)
WO (1) WO2021152398A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11413287B2 (en) 2018-11-16 2022-08-16 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
WO2023062595A1 (en) * 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl
WO2023079486A1 (en) * 2021-11-03 2023-05-11 Altavant Sciences Gmbh Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
CA3119912A1 (en) * 2018-11-14 2020-05-22 Altavant Sciences Gmbh A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin

Also Published As

Publication number Publication date
WO2021152398A1 (en) 2021-08-05
EP4096633A1 (en) 2022-12-07
AU2021212355A1 (en) 2022-08-18
JP2023512025A (ja) 2023-03-23
CN115379825A (zh) 2022-11-22
CA3165432A1 (en) 2021-08-05
MX2022009254A (es) 2022-09-07
US20230074252A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
US12201592B2 (en) Combinations of IRS/STAT3 dual modulators and anti-cancer agents for treating cancer
TWI831916B (zh) 包含tno155和瑞博西尼之藥物組合
US12370195B2 (en) Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
US10842792B2 (en) Deuterated baricitinib
JP6431478B2 (ja) Ｂ型肝炎ウイルスのｃｃｃｄｎａの転写の調節
KR20220156813A (ko) 로다트리스타트로 폐동맥 고혈압을 치료하기 위한 투여형태 및 방법
WO2017007658A1 (en) A combination for immune mediated cancer treatment
JP6357292B2 (ja) Ｃｎｋｓｒ１を阻害するための方法及び組成物
JP2008510830A (ja) ホスホジエステラーゼ５阻害剤（ｐｄｅ５）と併用するエンドセリンａ受容体（ｅｔａ）アンタゴニストおよびその使用
AU2013202305A1 (en) Methods for treating cancer using TOR kinase inhibitor combination therapy
US20210308117A1 (en) Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
CA3009283C (en) Orvepitant for the treatment of chronic cough
EP2753931A1 (en) Autoimmune and inflammatory disorder therapy
JP2023553533A (ja) 癌の処置のための併用療法
WO2020219423A1 (en) Combination therapies including inhibitors of dihydroorotate dehydrogenase
WO2018005328A1 (en) Deuterated bictegravir
WO2022226312A1 (en) Combination nucleotide pool depletion for treatment of viral infections and cancers
AU2025202348A1 (en) Use of maribavir for the treatment of and treatment regimens thereof
HK40079142A (en) Dosages and methods for treating pulmonary arterial hypertension with rodatristat
US20240262810A1 (en) Belumosudil Metabolites and Uses Thereof In The Treatment of Chronic Graft-Versus-Host Disease
KR102497051B1 (ko) 빅테그라비르의 대사물
CN117083283A (zh) 用于癌症治疗的联合疗法
EP4615440A1 (en) Pyrrolopyrimidine compositions for treatment of itk mediated conditions
WO2003066059A1 (en) Treatment of neuroblastoma
CN101137379A (zh) 用于治疗医学病症的cxcr4拮抗剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

D12-X000 Request for substantive examination rejected

St.27 status event code: A-1-2-D10-D12-exm-X000